Loading…
Foundation of the Federal Bar Association Charter Amendments Act of 2021
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
78pct
65d open
vs 9,698 other HR bills in the 117th — cohort avg 63d
Foundation of the Federal Bar Association Charter Amendments Act of 2021 This bill revises the federal charter for the Foundation of the Federal Bar Association. Specifically, the bill (1) eliminates the provision that requires the foundation to be incorporated and domiciled in the District of Columbia; and (2) requires the board of directors to decide, and specify in the bylaws, the location of the principal office. Additionally, the bylaws—not the charter—must provide for the terms of membership, the responsibilities of the board of directors, and the election of officers. A director or officer, in his or her corporate capacity, is prohibited from contributing to, supporting, or participating in political activities. The bill allows income and assets of the corporation to be used to reasonably compensate or reimburse expenses of an officer, director, or member; to award a grant to the Federal Bar Association chapter of an officer, director, or member; and to reasonably compensate employees. Furthermore, the bill expands a prohibition on loans for directors and officers to include members and employees. Finally, the bill specifies that on dissolution or final liquidation, any remaining assets must be distributed as provided by the board of directors instead of deposited in the Treasury.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (5)
2023 · second_quarter · Medicare/Medicaid
Received in the Senate and Read twice and referred to the Committee on the Judiciary.
Pursuant to section 11 of H. Res. 486, and the motion offered by Mr. McGovern, the following bills passed under suspension of the rules: H.R. 482; H.R. 704; H.R. 961, as amended; H.R. 1314; H.R. 2571, as amended; H.R. 2679, as amended; H.R. 2694; H.R. 2922, as amended; H.R. 3182; H.R. 3239; H.R. 3241, as amended; H.R. 3723; H.R. 3752; H.R. 3841; S. 409; and S. 1340. (consideration: CR H3026-3052; text: CR H3028-3029)
Passed/agreed to in House: Pursuant to section 11 of H. Res. 486, and the motion offered by Mr. McGovern, the following bills passed under suspension of the rules: H.R. 482; H.R. 704; H.R. 961, as amended; H.R. 1314; H.R. 2571, as amended; H.R. 2679, as amended; H.R. 2694; H.R. 2922, as amended; H.R. 3182; H.R. 3239; H.R. 3241, as amended; H.R. 3723; H.R. 3752; H.R. 3841; S. 409; and S. 1340.(consideration: CR H3026-3052; text: CR H3028-3029)
Pursuant to the provisions of H. Res. 486, proceedings on H.R. 2679 are considered vacated.
At the conclusion of debate, the Yeas and Nays were demanded and ordered. Pursuant to the provisions of clause 8, rule XX, the Chair announced that further proceedings on the motion would be postponed.
DEBATE - The House proceeded with forty minutes of debate on H.R. 2679.
Considered under suspension of the rules. (consideration: CR H2984-2986; text: CR H2984-2985)
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Issues related to prescription drug coverage and pharmacy benefits Regulatory and proposed legislative changes to Medicare Part D prescription drug benefits H.R.2666 -- Medicaid MVP for Patients Act S.652 / H.R.2630 -- Safe Step Act H.R.2679 -- Pharmacy Benefits Manager Accountability Act H.R.2691 - Transparent PRICE Act H.R.3281 - Transparent PRICE Act H.R.3282 - Promoting Transparency and Health Competition in Medicare Act H.R.3285 - Fairness for Patient Medications Act H.R.3561 - Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act S.1967 - Patients Before Middlemen (PBM) Act S.2052 - Protect Patient Access to Pharmacies Act S.2129 - Ensuring Access to Lower-Cost Medicines for Seniors Act H.R.4011 - Timely Access to Clinical Treatment Act S.1038 / H.R.1613 - Drug Price Transparency in Medicaid Act H.R.1770 - Equitable Community Access to Pharmacist Services Act S.1491 - Pharmacy and Medically Underserved Areas Enhancement Act S. 1375 / H.R.830 - Help Ensure Lower Patient (HELP) Copays Act H.R.1352 - Increasing Access to Biosimilars Act H.R.3799 - CHOICE Arrangement Act S.1130 - Health Care PRICE Transparency Act S.1131 - Drug Price Transparency Act H.R.3284 - Providers and Payers COMPETE Act Implementation of the Inflation Reduction Act of 2022, P.L. 169- Provisions on Medicare Part D modernization and drug price negotiation Implementation of Center for Medicare and Medicaid Services Final Rule, Contract Year 2023 Policy and Technical Changes to the Medicare Advantage and Medicare Prescription Drug Benefit Programs Final Rule, CMS-4192-F, CMS-1744-F, provisions related to changes in Pharmacy Direct and Indirect Renumeration
Client expense: $3,402,542 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2023 · second_quarter · Pharmacy
Issues related to pharmacy contracting with respect to drug pricing and pharmacy networks Regulatory and proposed legislative changes to Medicare Part D pharmacy contracting, pharmacy networks, and mail-service pharmacy S.113 - Prescription Pricing for the People Act S.127 - Pharmacy Benefit Manager Transparency Act H.R.2679 - Pharmacy Benefits Manager Accountability Act H.R.2691 - Transparent PRICE Act H.R.3281 - Transparent PRICE Act S.1339 - Pharmacy Benefit Manager Reform Act H.R.3282 - Promoting Transparency and Health Competition in Medicare Act H.R.3561 - Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act S.1967 - Patients Before Middlemen (PBM) Act S.2052 - Protect Patient Access to Pharmacies Act S.1038 / H.R.1613 - Drug Price Transparency in Medicaid Act H.R.1770 - Equitable Community Access to Pharmacist Services Act S.1491 - Pharmacy and Medically Underserved Areas Enhancement Act H.R.3284 - Providers and Payers COMPETE Act Implementation of the Inflation Reduction Act of 2022, P.L. 169- Provisions on Medicare Part D modernization and drug price negotiation Implementation of Center for Medicare and Medicaid Services Final Rule, Contract Year 2023 Policy and Technical Changes to the Medicare Advantage and Medicare Prescription Drug Benefit Programs Final Rule, CMS-4192-F, CMS-1744-F, provisions related to changes in Pharmacy Direct and Indirect Renumeration
Client expense: $3,402,542 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2023 · second_quarter · Health Issues
Issues related to prescription drug coverage and pharmacy benefits Issues related to the prescription drug marketplace, patents, and competition Regulatory and proposed legislative changes to Medicare Part D and Medicaid prescription drug benefits S.113 - Prescription Pricing for the People Act S.127 - Pharmacy Benefit Manager Transparency Act H.R.2666 - Medicaid MVP for Patients Act S.652 / H.R.2630 - Safe Step Act H.R.2679 - Pharmacy Benefits Manager Accountability Act H.R.2691 - Transparent PRICE Act H.R.3281 - Transparent PRICE Act S.1339 - Pharmacy Benefit Manager Reform Act S.1543 - A bill to require regulations concerning the disclosure of direct and indirect compensation from entities providing pharmacy benefit management services or third party administration services H.R.3282 - Promoting Transparency and Health Competition in Medicare Act H.R.3285 - Fairness for Patient Medications Act H.R.3561 - Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act S.1967 - Patients Before Middlemen (PBM) Act S.2052 - Protect Patient Access to Pharmacies Act S.2129 - Ensuring Access to Lower-Cost Medicines for Seniors Act H.R.4011 - Timely Access to Clinical Treatment Act S.1038 / H.R.1613 - Drug Price Transparency in Medicaid Act H.R.1770 - Equitable Community Access to Pharmacist Services Act S.1491 - Pharmacy and Medically Underserved Areas Enhancement Act S. 1375 / H.R.830 - Help Ensure Lower Patient (HELP) Copays Act S.954 / H.R.1488 - Affordable Insulin Now Act H.R.1503 - Prescription Information Modernization Act H.R.1352 - Increasing Access to Biosimilars Act S.1374 - Patient Right to Shop Act H.R.3799 - CHOICE Arrangement Act S.142 - Preserve Access to Affordable Generics and Biosimilars Act S.148 - Stop STALLING Act S.150 - Affordable Prescriptions for Patients Act S.574 - Increasing Prescription Drug Competition Act S.775 - Increasing Transparency in Generic Drug Applications Act H.R.1790 - Biologics Competition Act S.1067 - Ensuring Timely Access to Generics Act S.1114 - Expanding Access to Low-Cost Generics Act S.1120 - Improved Access to Affordable Medications Act S.1128 - Ensuring Access to Generic Medications Act S.1522 - A bill to require the Secretary of Health and Human Services to conduct a study on the designation of biosimilar biological products as interchangeable S.1130 - Health Care PRICE Transparency Act S.1131 - Drug Price Transparency Act H.R.3284 - Providers and Payers COMPETE Act Implementation of the Inflation Reduction Act of 2022, P.L. 169- Provisions on Medicare Part D modernization and drug price negotiation Implementation of Center for Medicare and Medicaid Services Final Rule, Contract Year 2023 Policy and Technical Changes to the Medicare Advantage and Medicare Prescription Drug Benefit Programs Final Rule, CMS-4192-F, CMS-1744-F, provisions related to changes in Pharmacy Direct and Indirect Renumeration
Client expense: $3,402,542 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2023 · second_quarter · Health Issues
H.R. 198: Drug Pricing Transparency and Accountability Act - Provisions related to the 340B Program H.R. 830/ S. 1375: HELP Copays Act - To amend title XXVII of the Public Health Service Act to apply additional payments, discounts, and other financial assistance towards the cost-sharing requirements of health insurance plans, and for other purposes H.R. 1790: Biologics Competition Act of 2023 - To direct the Secretary of Health and Human Services to evaluate the extent to which the substitution of interchangeable biological products is impacted by differences between the system for determining a biological product to be interchangeable and the system for assigning therapeutic equivalence ratings to drugs, and for other purposes H.R. 2500: Protecting Americans from Unsafe Drugs Act of 2023 H.R. 2679: Pharmacy Benefit Manager Accountability Act H.R. 2816: Pharmacy Benefit Manager Sunshine and Accountability Act H.R. 2940/S 1355 PASTEUR Act/Incentives to increase novel antibiotic medicines H.R. 2880: Protecting Patients Against PBM Abuses Act H.R. 3008: Drug Shortage Prevention Act of 2023 H.R. 3281: Transparent PRICE Act H.R. 3285: Fairness for Patient Medications Act H.R. 3290: To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program/Transparency Legislation H.R. 3433: Give Kids a Chance Act of 2023 H.R. 3561: Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 or PATIENT Act of 2023 H.R. 3791: Improving DATA in Public Health Act H.R. 3793: Ensuring Access to Lifesaving Drugs Act of 2023 H.R. 3810: Drug Origin Transparency Act of 2023 H.R. 4390: Protect 340B Act - Provisions related to 340B Program (117th Congress) H.R. 5376: Inflation Reduction Act of 2022 (P.L. 117-169)/Implementation of $0 Vaccine co-pay; maximum fair price provisions H.R. 7032: Increasing Transparency in Generic Drug Applications Act of 2022 - This bill requires the Food and Drug Administration to inform generic drug applicants, upon request or during review, whether the drug is qualitatively and quantitatively the same as the listed brand-name drug (and if not, the reasons why) (117th Congress) H.R. 7653: Modern Authentication of Pharmaceuticals Act of 2022 (117th Congress) S. 6: Biosimilar Red Tape Elimination Act (117th Congress) S. 113: Prescription Pricing for the People Act of 2023 - Provisions related to PBMs S. 127: Pharmacy Benefit Manager Transparency Act of 2023 - Provisions related to PBMs S. 148: Stop STALLING Act - Provisions related to citizen petitions S. 315: Taxpayer Research And Contributions Knowledge Act of 2023 or TRACK Act of 2023 - To direct the Secretary of Health and Human Services and other Federal officials to compile into a searchable database information relating to Federal support for biomedical research and development, and for other purposes. S. 476: Maintaining Investments in New Innovation Act S. 775: Increasing Transparency in Generic Drug Applications Act S. 1128: Ensuring Access to Generic Medications Act S. 898: Fair Accountability and Innovative Research Drug Pricing Act of 2021 - Provisions related to drug pricing (117th Congress) S. 1967: Patients Before Middlemen (PBM Act) S. 1067: Ensuring Timely Access to Generics Act of 2023 S. 1114: Expanding Access to Low-Cost Generics Act 2023 S. 1214: RARE Act - To set forth limitations on exclusive approval or licensure of drugs designated for rare diseases or conditions S. 1264: SMART Prices Act - Provisions related to drug pricing reform S. 1339: Pharmacy Benefit Manager Reform Act - Provisions related to PBMs S. 1355: PASTEUR Act of 2023 - Provisions related to antimicrobial resistance policy issues S. 1375: HELP Copays Act - To amend title XXVII of the Public Health Service Act to apply additional payments, discounts, and other financial assistance towards the cost-sharing requirements of health insurance plans, and for other purposes S. 1542: Delinking Revenue from Unfair Gouging Act or DRUG Act - Provisions related to PBMs S. 3799: Prepare for and Respond to Existing Viruses, Emerging New Threats, and Pandemics Act or PREVENT Pandemics Act (117th Congress) Pharmacy Benefit Manager reform and policy issues Pandemic and All-Hazards Preparedness Reauthorization Act (PAHPRA) Cancer Moonshot Initiative 21st Century Cures 2.0 Drug cost and pricing policy issues Principles for drug pricing reform Drug importation policy issues Accelerated approval policy issues FDA regulatory approval authority policy issues Competition policy issues Orphan Drug Act policy issues Antimicrobial resistance (AMR) policy issues Mental health policy issues High deductible health plans/HSA policy issues Supply chain policy issues Real world evidence policy issues Clinical trial diversity policy issues Prescription drug abuse policy issues 340B drug discount program policy issues Patient assistance program policy issues Biosimilar approval and reimbursement policy issues Drug shortages policy issues COVID-19 policy issues Pandemic preparedness policy issues Defense Production Act policy issues Cybersecurity policy issues Anticounterfeiting policy issues Chronic Kidney Disease Improvement in Research and Treatment Act. H.R.2534 - PROTECT 340B Act of 2023 House Draft Language for PAHPA Reauthorization HR 3665 - Defending American Jobs and Investment Act Senate Draft Language for PAHPA Reauthorization Pandemic and All Hazards Preparedness Act reauthorization (discussion draft) Labor HHS appropriations (ongoing discussion) Under Taxed Profit Rule, Ways and Means Committee discussion Vaccine Injury Compensation Program reform discussion
Client expense: $900,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
2023 · second_quarter · Health Issues
H.R. 198: Drug Pricing Transparency and Accountability Act - Provisions related to the 340B Program H.R. 830: HELP Copays Act - To amend title XXVII of the Public Health Service Act to apply additional payments, discounts, and other financial assistance towards the cost-sharing requirements of health insurance plans, and for other purposes H.R. 1790: Biologics Competition Act of 2023 - To direct the Secretary of Health and Human Services to evaluate the extent to which the substitution of interchangeable biological products is impacted by differences between the system for determining a biological product to be interchangeable and the system for assigning therapeutic equivalence ratings to drugs, and for other purposes H.R. 2500: Protecting Americans from Unsafe Drugs Act of 2023 H.R. 2534: PROTECT 340B Act of 2023 - Provisions related to the 340B program H.R. 2679: Pharmacy Benefit Manager Accountability Act H.R. 2816: Pharmacy Benefit Manager Sunshine and Accountability Act H.R. 2880: Protecting Patients Against PBM Abuses Act H.R. 3008: Drug Shortage Prevention Act of 2023 H.R. 3281: Transparent PRICE Act H.R. 3285: Fairness for Patient Medications Act H.R. 3290: To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program H.R. 3433: Give Kids a Chance Act of 2023 H.R. 3561: Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 or PATIENT Act of 2023 H.R. 3791: Improving DATA in Public Health Act H.R. 3793: Ensuring Access to Lifesaving Drugs Act of 2023 H.R. 3810: Drug Origin Transparency Act of 2023 H.R. 5376: Inflation Reduction Act of 2022 (P.L. 117-169) H.R. 7032: Increasing Transparency in Generic Drug Applications Act of 2022 (117th Congress) H.R. 7653: Modern Authentication of Pharmaceuticals Act of 2022 (117th Congress) S. 6: Biosimilar Red Tape Elimination Act (117th Congress) S. 113: Prescription Pricing for the People Act of 2023 - Provisions related to PBMs S. 127: Pharmacy Benefit Manager Transparency Act of 2023 - Provisions related to PBMs S. 148: Stop STALLING Act - Provisions related to citizen petitions S. 315: Taxpayer Research And Contributions Knowledge Act of 2023 or TRACK Act of 2023 - To direct the Secretary of Health and Human Services and other Federal officials to compile into a searchable database information relating to Federal support for biomedical research and development, and for other purposes S. 476: Maintaining Investments in New Innovation Act S. 775: Increasing Transparency in Generic Drug Applications Act S. 1128: Ensuring Access to Generic Medications Act S. 935: Fair Accountability and Innovative Research Drug Pricing Act of 2023 - Provisions related to drug pricing S. 1067: Ensuring Timely Access to Generics Act of 2023 S. 1114: Expanding Access to Low-Cost Generics Act 2023 S. 1214: RARE Act - To set forth limitations on exclusive approval or licensure of drugs designated for rare diseases or conditions S. 1264: SMART Prices Act - Provisions related to drug pricing reform S. 1339: Pharmacy Benefit Manager Reform Act - Provisions related to PBMs S. 1355: PASTEUR Act of 2023 - Provisions related to antimicrobial resistance policy issues S. 1375: HELP Copays Act - To amend title XXVII of the Public Health Service Act to apply additional payments, discounts, and other financial assistance towards the cost-sharing requirements of health insurance plans, and for other purposes S. 1542: Delinking Revenue from Unfair Gouging Act or DRUG Act - Provisions related to PBMs S. 3799: Prepare for and Respond to Existing Viruses, Emerging New Threats, and Pandemics Act or PREVENT Pandemics Act (117th Congress) Pharmacy Benefit Manager reform and policy issues Pandemic and All-Hazards Preparedness Reauthorization Act (PAHPRA) Cancer Moonshot Initiative 21st Century Cures 2.0 Drug cost and pricing policy issues Principles for drug pricing reform Drug importation policy issues Accelerated approval policy issues FDA regulatory approval authority policy issues Competition policy issues Orphan Drug Act policy issues Antimicrobial resistance (AMR) policy issues Mental health policy issues High deductible health plans/HSA policy issues Supply chain policy issues Real world evidence policy issues Clinical trial diversity policy issues Prescription drug abuse policy issues 340B drug discount program policy issues Patient assistance program policy issues Biosimilar approval and reimbursement policy issues Drug shortages policy issues COVID-19 policy issues Pandemic preparedness policy issues Defense Production Act policy issues Cybersecurity policy issues Anticounterfeiting policy issues
Client expense: $6,300,000 · Firm income: Not reported
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE
2023 · second_quarter · Health Issues
PBM Transparency-Issues concerning PBM reporting of rebates and payments through the pharmaceutical supply chain. S. 127, The Pharmacy Benefit Manager Transparency Act of 2023," provisions related to the Federal Trade Commission regulation of PBMs. H.R. 4011, Timely Access to Clinical Treatment (TACT) Act of 2023, provisions on pharmacy access standards. Issues related to cost-sharing for insulin and other therapies in the commercial market. S. 1339, the Pharmacy Benefit Manager Reform Act provisions related to PBM disclosure, fee pass through and fee structures. H.R. 3862, Improving Transparency to Lower Drug Cost Act of 2021 (117th Congress)-provisions related to PBM transparency and disclosure. H.R. 3561, The PATIENT Act, provisions related to disclosure of drug price concessions and highly-rebated drugs. H.R. 37999, the CHOICE Act, potential amendments related to PBM pharmacy contracting practices. Issues related to patient cost-sharing and drug coupons. H.R. 3281/H.R. 2681, The Transparence PRICE Act, issues related to disclosure of drug price concessions. H.R. 2679, Pharmacy Benefit Manager Accountability Act, provisions related to client disclosure of drug price concessions particularly coupon use.
Client expense: $80,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · fourth_quarter · Government Issues
H.R. 2679 (Foundation of the Federal Bar Association Charter Amendments Act of 2021), all provisions Support for prompt action on filling judicial vacancies and on judicial nominations Support for improved security for federal courthouses and federal judges and judiciary personnel H.R. 4885 and S. 2535 (JUDGES Act), all provisions H.R. 4886 (District Court Judgeships Act of 2021), all provisions Issues pertaining generally to the federal legal system H.R. 4436 and S. 2340 (Daniel Anderl Judicial Security and Privacy Act of 2021), all provisions H.R. 7776 (James M. Inhofe National Defense Authorization Act for Fiscal Year 2023), Sections 5931-5939, regarding the Daniel Anderl Judicial Security and Privacy Act of 2022
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · third_quarter · Government Issues
H.R. 2679 (Foundation of the Federal Bar Association Charter Amendments Act of 2021), all provisions Support for prompt action on filling judicial vacancies and on judicial nominations Support for improved security for federal courthouses and federal judges and judiciary personnel H.R. 4885 and S. 2535 (JUDGES Act), all provisions H.R. 4886 (District Court Judgeships Act of 2021), all provisions Issues pertaining generally to the federal legal system H.R. 4436 and S. 2340 (Daniel Anderl Judicial Security and Privacy Act of 2021), all provisions H.R. 5720 and S. 3059 (Courthouse Ethics and Transparency Act), all provisions H.R. 5844 and S. 2614 (Open Courts Act of 2021), all provisions H.R. 4827 and S. 2553 (Judiciary Accountability Act of 2021), all provisions H.R. 7900 (National Defense Authorization Act for Fiscal Year 2023), regarding judicial security
Client expense: Not reported · Firm income: $50,000
2022 · second_quarter · Government Issues
H.R. 2679 (Foundation of the Federal Bar Association Charter Amendments Act of 2021), all provisions Support for prompt action on filling judicial vacancies and on judicial nominations Support for improved security for federal courthouses and federal judges and judiciary personnel H.R. 4885 and S. 2535 (JUDGES Act), all provisions H.R. 4886 (District Court Judgeships Act of 2021), all provisions Issues pertaining generally to the federal legal system H.R. 4436 and S. 2340 (Daniel Anderl Judicial Security and Privacy Act of 2021), all provisions H.R. 5720 and S. 3059 (Courthouse Ethics and Transparency Act), all provisions H.R. 5844 and S. 2614 (Open Courts Act of 2021), all provisions H.R. 4827 and S. 2553 (Judiciary Accountability Act of 2021), all provisions
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · first_quarter · Government Issues
H.R. 2679 (Foundation of the Federal Bar Association Charter Amendments Act of 2021), all provisions Support for prompt action on filling judicial vacancies and on judicial nominations Support for improved security for federal courthouses and federal judges and judiciary personnel H.R. 4885 and S. 2535 (JUDGES Act), all provisions H.R. 4886 (District Court Judgeships Act of 2021), all provisions Issues pertaining generally to the federal legal system H.R. 4436 and S. 2340 (Daniel Anderl Judicial Security and Privacy Act of 2021), all provisions H.R. 5720 and S. 3059 (Courthouse Ethics and Transparency Act), all provisions H.R. 5844 and S. 2614 (Open Courts Act of 2021), all provisions
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2021 · fourth_quarter · Government Issues
H.R. 2679 (Foundation of the Federal Bar Association Charter Amendments Act of 2021), all provisions Support for prompt action on filling judicial vacancies and on judicial nominations Support for improved security for federal courthouses and federal judges and judiciary personnel H.R. 4885 and S. 2535 (JUDGES Act), all provisions H.R. 4886 (District Court Judgeships Act of 2021), all provisions Issues pertaining generally to the federal legal system H.R. 4436 and S. 2340 (Daniel Anderl Judicial Security and Privacy Act of 2021), all provisions H.R. 5720 and S. 3059 (Courthouse Ethics and Transparency Act), all provisions H.R. 5844 and S. 2614 (Open Courts Act of 2021), all provisions
Client expense: Not reported · Firm income: $50,000
2021 · third_quarter · Government Issues
H.R. 2679 (Foundation of the Federal Bar Association Charter Amendments Act of 2021), all provisions Support for prompt action on filling judicial vacancies and on judicial nominations Support for improved security for federal courthouses and federal judges and judiciary personnel H.R. 4885 and S. 2535 (JUDGES Act), all provisions H.R. 4886 (District Court Judgeships Act of 2021), all provisions Issues pertaining generally to the federal legal system
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2021 · second_quarter · Government Issues
H.R. 2679 (Foundation of the Federal Bar Association Charter Amendments Act of 2021), all provisions Support for prompt action on filling judicial vacancies and on judicial nominations Issues pertaining generally to the federal legal system
Client expense: Not reported · Firm income: $10,000
Ms. Jackson Lee moved to suspend the rules and pass the bill, as amended.
Referred to the House Committee on the Judiciary.
Introduced in House
Congress.gov source codes: 1000, Intro-H
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Government targets: HOUSE OF REPRESENTATIVES, SENATE